Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

84
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
84
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

4.0K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.0K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

177
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
177
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

122
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
122

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Opioid Use Disorder and Treatment Uptake among Patients with Rheumatic Conditions in the All of Us Research Program: A Descriptive Analysis.

Arthritis care & research·2026
Same author

Assessing Reliability of an Electronic Gout Flare Assessment Protocol.

Arthritis care & research·2026
Same author

"More guidelines than rules": reconsidering key gaps in the 2025 American College of Rheumatology treatment recommendations for systemic lupus erythematosus: comment on the article by Sammaritano et al.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Cortical plasticity of the tactile mirror system in borderline personality disorder.

Cortex; a journal devoted to the study of the nervous system and behavior·2026
Same author

Genetic Variations in the M6A Modification Pathway as Potential Predictors of Imatinib Secondary Resistance in Gastrointestinal Stromal Tumors.

Journal of clinical medicine·2026
Same author

Measurement of haemolytic anaemia in a novel treatment response measure for SLE clinical trials.

Lupus science & medicine·2026

Related Experiment Video

Updated: Jun 24, 2025

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

2.9K

Hydroxychloroquine Dose and Hospitalizations for Active Lupus.

Jacquelyn Nestor1, Hyon Choi1, Christian Mancini1

  • 1Massachusetts General Hospital, Harvard Medical School, Boston.

Arthritis & Rheumatology (Hoboken, N.J.)
|June 4, 2024
PubMed
Summary

Lower doses of hydroxychloroquine (HCQ) increase hospitalizations for active systemic lupus erythematosus (SLE). Balancing HCQ retinopathy risks with SLE activity is crucial for patient management.

More Related Videos

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine
08:31

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine

Published on: October 11, 2019

10.3K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.9K

Related Experiment Videos

Last Updated: Jun 24, 2025

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

2.9K
Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine
08:31

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine

Published on: October 11, 2019

10.3K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.9K

Area of Science:

  • Rheumatology
  • Clinical Pharmacology

Background:

  • Systemic lupus erythematosus (SLE) is a chronic autoimmune disease.
  • Hydroxychloroquine (HCQ) is a common treatment for SLE, but optimal dosing strategies require further investigation.
  • Understanding HCQ dosage impact on SLE flares is critical for patient outcomes.

Purpose of the Study:

  • To evaluate the association between hydroxychloroquine (HCQ) dosage and the risk of hospitalizations for active systemic lupus erythematosus (SLE).

Main Methods:

  • A case-crossover study design was employed, analyzing data from patients with SLE between 2011 and 2021.
  • HCQ doses were categorized by weight-based (≤5 vs >5 mg/kg/day) and non-weight-based (<400 vs 400 mg/day) metrics.
  • Conditional logistic regression was used to calculate adjusted odds ratios (ORs) for SLE hospitalizations.

Main Results:

  • Lower weight-based HCQ doses (≤5 mg/kg/day) were associated with a 4.20-fold increased risk of SLE hospitalizations.
  • Lower non-weight-based HCQ doses (<400 mg/day) showed a 3.39-fold increased risk of SLE hospitalizations.
  • These associations remained significant after adjusting for covariates.

Conclusions:

  • Lower hydroxychloroquine (HCQ) doses are linked to a higher risk of hospitalizations for active systemic lupus erythematosus (SLE).
  • The potential for HCQ-induced retinopathy must be weighed against the increased short-term and cumulative risks of SLE disease activity.
  • Optimizing HCQ dosage is essential for managing SLE and preventing severe disease flares.